文献速递产科母胎医学

妊娠期巨细胞病毒感染:科学现状综述

Cytomegalovirus infection during pregnancy: state of the science.
PubMed 文献 · Am J Obstet Gynecol · 2020-02-24

巨细胞病毒是最常见的先天性感染,影响0.5-2%活产儿,是非遗传性先天性感音神经性听力损失和神经损伤的主要原因。先天性感染可发生于母体原发或非原发感染,感音神经性后遗症主要局限于早孕期原发感染,高达40-50%感染新生儿出现后遗症。孕14周前血清学检测对识别围绕受孕3个月内的原发感染至关重要,但对孕前已免疫者无信息价值。

要点

  • 早孕期原发感染后高达40-50%新生儿出现后遗症,孕14周前血清学筛查关键。
  • 胎儿小、肠管回声增强、积液或脑异常时应怀疑先天性巨细胞病毒感染。
  • 从原发感染诊断至羊膜腔穿刺期间使用伐昔洛韦可降低垂直传播率。

核心结论

  • 先天性巨细胞病毒感染是公共卫生挑战,医疗提供者应重新评估早孕期和出生时的筛查方案。

研究设计与样本

  • 本文为综述,汇总妊娠期巨细胞病毒感染的诊断、产前和产后管理相关科学证据。

主要发现

  • 巨细胞病毒影响0.5-2%活产儿,是先天性感音神经性听力损失和神经损伤的主要非遗传原因。
  • 早孕期原发感染后高达40-50%感染新生儿出现后遗症。
  • 常规超声预测新生儿症状的敏感性约25%,系列靶向超声和MRI对已知感染胎儿的脑异常敏感性大于95%。
  • 随机对照试验(90名孕妇)中,从原发感染诊断至羊膜腔穿刺使用伐昔洛韦将垂直传播率从29.8%降至11.1%。
  • II期开放标签试验中,口服伐昔洛韦(8 g/d)治疗轻度症状胎儿后分娩无症状新生儿的比例为82%,未治疗历史队列为43%。

关键数值与推荐

  • 孕14周前血清学检测对识别围绕受孕3个月内的原发感染至关重要,但对孕前已免疫者无信息价值。
  • 胎儿诊断通过孕17周起羊膜腔穿刺进行。
  • 预防包括双亲从孕前至孕14周避免接触感染者体液,尤其幼儿。
  • 候选疫苗在预防巨细胞病毒感染方面2年以上保护率未超过75%。
  • 两项随机对照试验未发现巨细胞病毒超免疫球蛋白降低垂直传播风险的获益。

临床怎么用

  • 对孕早期原发感染孕妇可考虑使用伐昔洛韦以降低垂直传播率。
  • 产前超声发现胎儿小于孕龄、肠管回声增强、积液或脑异常时应怀疑先天性巨细胞病毒感染。
  • 对已知感染胎儿进行系列靶向超声和MRI以评估脑异常。
  • 症状性新生儿使用缬更昔洛韦可能改善听力和神经症状,但程度和疗程尚待确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cytomegalovirus is the most common congenital infection, affecting 0.5-2% of all live births and the main nongenetic cause of congenital sensorineural hearing loss and neurological damage. Congenital cytomegalovirus can follow maternal primary infection or nonprimary infection. Sensorineurological morbidity is confined to the first trimester with up to 40-50% of infected neonates developing sequelae after first-trimester primary infection. Serological testing before 14 weeks is critical to identify primary infection within 3 months around conception but is not informative in women already immune before pregnancy. In Europe and the United States, primary infection in the first trimester are mainly seen in young parous women with a previous child younger than 3 years. Congenital cytomegalovirus should be evoked on prenatal ultrasound when the fetus is small for gestation and shows echogenic bowel, effusions, or any cerebral anomaly. Although the sensitivity of routine ultrasound in predicting neonatal symptoms is around 25%, serial targeted ultrasound and magnetic resonance imaging of known infected fetuses show greater than 95% sensitivity for brain anomalies. Fetal diagnosis is done by amniocentesis from 17 weeks. Prevention consists of both parents avoiding contact with body fluids from infected individuals, especially toddlers, from before conception until 14 weeks. Candidate vaccines failed to provide more than 75% protection for >2 years in preventing cytomegalovirus infection. Medical therapies such as cytomegalovirus hyperimmune globulins aim to reduce the risk of vertical transmission but 2 randomized controlled trials have not found any benefit. Valaciclovir given from the diagnosis of primary infection up to amniocentesis decreased vertical transmission rates from 29.8% to 11.1% in the treatment group in a randomized controlled trial of 90 pregnant women. In a phase II open-label trial, oral valaciclovir (8 g/d) given to pregnant women with a mildly symptomatic fetus was associated with a higher chance of delivering an asymptomatic neonate (82%), compared with an untreated historical cohort (43%). Valganciclovir given to symptomatic neonates is likely to improve hearing and neurological symptoms, the extent of which and the duration of treatment are still debated. In conclusion, congenital cytomegalovirus infection is a public health challenge. In view of recent knowledge on diagnosis and pre- and postnatal management, health care providers should reevaluate screening programs in early pregnancy and at birth.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Leruez-Ville M, Foulon I, Pass R, et al. Cytomegalovirus infection during pregnancy: state of the science. Am J Obstet Gynecol. 2020. PMID: 32105678. doi:10.1016/j.ajog.2020.02.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。